Redesignation to Spearhead BHB’s Restructuring KUALA LUMPUR, 19 JUNE 2023 – Boustead Holdings Berhad (“BHB” or “the Group”) is pleased to announce the redesignation of the Group’s Non-Independent Non-Executive Chairman Dato’ Ahmad Nazim Abd Rahman as Executive Chairman, effective today. Dato’ Nazim Rahman, who is also the Chief Executive of Lembaga Tabung Angkatan Tentera…
KUALA LUMPUR, 15 JUNE 2023 – Boustead Holdings Berhad (“BHB” or “the Group”) refers to the speculative news articles on the sale of Boustead Petroleum Marketing Sdn. Bhd., also known as BHPetrol. We wish to provide clarifications on the speculation based on unnamed sources in the article. It must be stressed that we have not…
PETALING JAYA, June 15, 2023 – Boustead Holdings Berhad (BHB or the Group) today held its 61st Annual General Meeting (AGM), which was held virtually with shareholders participating via livestreaming. Non-Independent Non-Executive Chairman, Dato’ Ahmad Nazim Abd Rahman, chaired the meeting, which was also attended by other members of the Board of Directors. BHB’s financial…
Remains Focused on Strengthening Resilience KUALA LUMPUR, May 29, 2023 – For the first quarter ended 31 March 2023, Boustead Holdings Berhad (BHB) recorded a revenue of RM3.2 billion. Nevertheless, the Group’s bottom line was impacted by weaker contributions from its Divisions. This resulted in a loss after tax of RM43 million for the…
KUALA LUMPUR, 2 MARCH 2023 – Boustead Holdings Berhad (Boustead) today announces the appointment of Dato’ Ahmad Nazim Abd Rahman as the Group’s new non-Independent non-Executive Chairman. Dato’ Nazim Rahman, age 47, holds a Bachelor of Laws (Honours) from the International Islamic University Malaysia. He was a J William Fulbright Scholar at Georgetown University, United…
KUALA LUMPUR, February 28, 2023 – Boustead Holdings Berhad (BHB) posted a consolidated profit after tax of RM129 million for the financial year ended 31 December 2022. Profit before tax (PBT) stood at RM446 million while revenue increased to RM15.1 billion. The Group’s bottom line was primarily impacted by impairment at the Pharmaceutical Division by…